Henley-in-Arden headquartered Mercia invested over 48 million nationally in 2017, highlighting it as one of the UK’s most active technology investors and a key source of funding and scaling for regional SMEs.
The company opened new offices in Birmingham, Sheffield and Leeds and continued to expand its team. It now has over 70 people in eight locations across the UK, and has partnerships with 19 universities.
It also increased its third-party funds under management from £220 million at the start of the year to in excess of £350 million as at 31 December 2017.
During 2017 Mercia invested nearly £26 million nationally from its third party funds under management and £22.5 million in direct investments in portfolio companies including Oxford Genetics, nDreams, Warwick Audio Technologies, Impression Technologies, Medherant and Intechnica.
Mark Payton, Chief Executive of Mercia Technologies PLC, said: “During 2017 Mercia has continued to strengthen its regional presence, build its investment portfolio, its team and its network of university partners.
“The Government’s recent Patient Capital Review highlighted the importance of long-term investment to build the businesses of the future. Mercia’s Complete Capital Solution model does just that. By identifying innovative regional businesses with high-growth potential, and providing them with patient investment and practical support at each stage of the cycle, we can turn them into global players whilst delivering value for our shareholders.”